Financial Data and Key Metrics Changes - The company reported revenue of $86.2 million for Q2 2025, a decrease of $800,000 or 1% compared to Q2 2024, primarily due to a $12.5 million decrease in revenue from dermatological tests, offset by an $11.7 million increase from non-dermatological tests [17][18] - Adjusted revenue for Q2 2025 was $86.2 million, also a decrease of 1% compared to the previous year [18] - The gross margin for Q2 2025 was 77.3%, down from 80.7% in Q2 2024, while adjusted gross margin was 79.5% compared to 83.2% in the same period last year [19] - Net income for Q2 2025 was $4.5 million, compared to $8.9 million in Q2 2024, with diluted earnings per share at $0.15 versus $0.31 in the prior year [22] Business Line Data and Key Metrics Changes - For DecisionDx Melanoma, the company delivered 9,981 test reports in Q2 2025, a sequential increase of approximately 16% compared to Q1 2025 and a year-over-year increase of about 4% compared to Q2 2024 [7][8] - DecisionDx SCC test reports totaled 4,762 in Q2 2025, with revenue from this test estimated at just above $15 million [10][17] - Tissue Cypher test reports reached 9,170 in Q2 2025, representing a 92% year-over-year growth compared to Q2 2024 [12] Market Data and Key Metrics Changes - The company expects continued solid growth in the second half of 2025, reiterating expectations for high single-digit volume growth for DecisionDx Melanoma for the full year [8] - The collaboration with the National Cancer Institute's SEER program is ongoing, enhancing the clinical management of melanoma patients [9] Company Strategy and Development Direction - The company is focused on investing in near-term growth initiatives, including expanding clinical evidence and optimizing the commercial team [6] - The M&A strategy aims to complement the existing portfolio to drive mid- to long-term value creation, with a focus on tests that have established reimbursement and high clinical value [24] - The company is pursuing a multi-omics approach for improved test value in Barrett's esophagus and other GI diseases [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical value of their tests and the ability to create value for shareholders in the near and long term [26] - The company is optimistic about the potential for their atopic dermatitis test and expects to launch it by the end of 2025 [14][44] - Management acknowledged challenges in the reimbursement environment but remains committed to providing innovative tests that significantly impact patient care [47] Other Important Information - The company ended Q2 2025 with $275.9 million in cash, cash equivalents, and marketable securities, positioning it well for future investments [6][23] - The company has submitted reconsideration requests for DecisionDx SCC to Novitas and MolDx, with expectations of a response from MolDx by Labor Day [58][59] Q&A Session Summary Question: Plans for FDA approval after breakthrough designation for DecisionDx Melanoma - Management is moving forward with efforts to seek FDA submission but did not disclose specific timing [30] Question: Payment status for DecisionDx SCC volume - The company receives episodic payments on commercial claims, but these are not significant percentages [31][33] Question: Insights on GI sales rep productivity - The sales team is expected to reach full productivity in the third and fourth quarters of 2025 [36] Question: Reimbursement outlook for atopic dermatitis test - The company is pursuing multiple reimbursement avenues and expects limited revenue impact in 2026 [44] Question: Continuation of DecisionDx SCC offering - The company plans to keep the test available in the marketplace while moderating volume due to educational sales efforts [46] Question: Drivers for revenue guidance increase - The company raised its revenue guidance due to strong business drivers and historical seasonal trends [48] Question: Growth expectations for Tissue Cypher - The company anticipates continued growth in Tissue Cypher volumes without significant seasonality expected [56] Question: Progress with private payers for DecisionDx Melanoma - The company continues to generate data to support payer engagement, despite resistance from the payer community [102]

Empowering people, informing care decisions August 2025 ©2025 Castle Biosciences 1 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. These forward-looking statements include, but are not limited to, statements concerning: our positioning for continued growth ...

PART I. FINANCIAL INFORMATION [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) Unaudited condensed consolidated financial statements for Q2 and H1 2025 show a **$21.3 million net loss** for the six months, driven by increased amortization of intangible assets Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $82,233 | $119,709 | | Marketable investment securities | $193,697 | $173,421 | | Accounts receivable, net | $52,311 | $51,218 | | Total current assets | $348,668 | $360,154 | | Total assets | $544,729 | $531,235 | | **Liabilities & Equity** | | | | Total current liabilities | $50,890 | $49,392 | | Long-term debt | $8,096 | $9,745 | | Total liabilities | $89,353 | $75,400 | | Total stockholders' equity | $455,376 | $455,835 | Condensed Consolidated Statements of Operations Highlights (in thousands, except per share data) | Metric | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 | | :--- | :--- | :--- | :--- | :--- | | Net Revenues | $86,188 | $87,002 | $174,176 | $159,976 | | Total operating expenses | $90,439 | $81,990 | $206,355 | $160,435 | | Operating (loss) income | $(4,251) | $5,012 | $(32,179) | $(459) | | Net income (loss) | $4,523 | $8,920 | $(21,325) | $6,386 | | Diluted EPS | $0.15 | $0.31 | $(0.74) | $0.22 | Condensed Consolidated Statements of Cash Flows Highlights (in thousands) | Cash Flow Activity | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $14,785 | $17,163 | | Net cash used in investing activities | $(50,809) | $(41,118) | | Net cash (used in) provided by financing activities | $(1,452) | $10,686 | | **Net change in cash and cash equivalents** | **$(37,476)** | **$(13,269)** | - In Q1 2025, the company discontinued its IDgenetix test, leading to an accelerated amortization expense of approximately **$20.1 million** as the related intangible asset was fully amortized by March 31, 2025[77](index=77&type=chunk) - In May 2025, the company acquired Capsulomics, Inc. for **$28.2 million**, accounted for as an asset acquisition with a 12-year useful life for the developed technology[34](index=34&type=chunk)[78](index=78&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=29&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses an **8.9% increase in H1 2025 net revenues** to **$174.2 million**, offset by a **$21.3 million net loss** due to accelerated amortization and the discontinuation of IDgenetix, alongside capital uses for operations and a new headquarters [Overview and Test Portfolio](index=29&type=section&id=Overview%20and%20Test%20Portfolio) Castle Biosciences, a molecular diagnostics company, discontinued its IDgenetix test in May 2025, focusing on dermatologic cancers, Barrett's esophagus, and uveal melanoma, with DecisionDx-Melanoma and DecisionDx-SCC as primary revenue drivers - The company's portfolio includes **five proprietary multi-analyte assays** with algorithmic analysis (MAAA) tests across dermatology, gastroenterology, and ophthalmology[121](index=121&type=chunk) - The IDgenetix pharmacogenomic test for mental health conditions was discontinued in **May 2025** after careful assessment[129](index=129&type=chunk)[152](index=152&type=chunk) - In July 2025, the FDA granted **Breakthrough Device designation** to the DecisionDx-Melanoma test, aiming to expedite its development and review[149](index=149&type=chunk) [Reimbursement and Test Reports](index=30&type=section&id=Reimbursement%20and%20Test%20Reports) Reimbursement is critical, with DecisionDx-SCC losing Medicare coverage in April 2025, yet overall test report volume grew **10.8%** in H1 2025, driven by a **102.2% increase** in TissueCypher volumes - Novitas finalized non-coverage for the DecisionDx-SCC test, effective **April 24, 2025**, following similar recommendations from Palmetto and Noridian in 2024[122](index=122&type=chunk)[138](index=138&type=chunk) Test Reports Delivered | Test | 6 Months 2025 | 6 Months 2024 | % Change | | :--- | :--- | :--- | :--- | | DecisionDx-Melanoma | 18,602 | 17,969 | +3.5% | | DecisionDx-SCC | 9,137 | 7,854 | +16.3% | | TissueCypher | 16,602 | 8,211 | +102.2% | | IDgenetix (discontinued) | 3,605 | 8,981 | -59.9% | | **Grand Total** | **50,976** | **45,990** | **+10.8%** | [Results of Operations](index=37&type=section&id=Results%20of%20Operations) Q2 2025 revenues decreased **0.9%** to **$86.2 million**, with H1 revenues up **8.9%** to **$174.2 million**, but a **$21.3 million net loss** resulted from a **$25.8 million increase** in amortization expense due to the IDgenetix write-off Revenue Disaggregation (in thousands) | Revenue Type | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 | | :--- | :--- | :--- | :--- | :--- | | Dermatologic | $56,297 | $68,828 | $119,259 | $128,163 | | Non-Dermatologic | $29,891 | $18,174 | $54,917 | $31,813 | | **Total net revenues** | **$86,188** | **$87,002** | **$174,176** | **$159,976** | Gross Margin Comparison | Period | Gross Margin % 2025 | Gross Margin % 2024 | | :--- | :--- | :--- | | Three Months Ended June 30 | 77.3% | 80.7% | | Six Months Ended June 30 | 63.1% | 79.4% | - Amortization of acquired intangible assets increased by **$25.8 million** for the six months ended June 30, 2025, primarily due to the full amortization of IDgenetix's remaining carrying value by March 31, 2025[206](index=206&type=chunk) [Liquidity and Capital Resources](index=43&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2025, the company maintained strong liquidity with **$82.2 million** in cash and **$193.7 million** in marketable securities, with a new **$44.2 million corporate headquarters** under construction and access to a **$25.0 million line of credit** - As of June 30, 2025, the company held **$82.2 million** in cash and cash equivalents and **$193.7 million** in marketable investment securities[210](index=210&type=chunk) - A new corporate headquarters, estimated to cost **$44.2 million**, is under construction with **$14.0 million** spent in 2025, expected completion in early 2026[213](index=213&type=chunk) - The company has an undrawn **$25.0 million line of credit** available until September 30, 2025[210](index=210&type=chunk)[225](index=225&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=46&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company faces market risks from interest rate fluctuations on its **$10.0 million floating-rate term debt**, inflationary pressures on costs, and equity price volatility from its **$3.3 million equity securities portfolio** - The company is exposed to interest rate risk through its **$10.0 million term loan**, which bears a floating interest rate tied to the WSJ Prime Rate[240](index=240&type=chunk) - As of June 30, 2025, the company held equity securities with a fair value of **$3.3 million**, exposing it to equity price risk[242](index=242&type=chunk) [Controls and Procedures](index=47&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of June 30, 2025, with no material changes in internal control over financial reporting during Q2 2025 - Management concluded that as of June 30, 2025, the company's disclosure controls and procedures were effective at a reasonable assurance level[244](index=244&type=chunk) - No material changes in internal control over financial reporting occurred during Q2 2025[245](index=245&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=48&type=section&id=Item%201.%20Legal%20Proceedings) The company is cooperating with a subpoena from the U.S. Department of Health and Human Services, Office of Inspector General, regarding federal healthcare program claims from 2015-2024, with the outcome and financial impact currently unknown - On February 1, 2024, the company received a subpoena from the Department of Health and Human Services, Office of Inspector General, concerning claims submitted for payment under federal healthcare programs[98](index=98&type=chunk)[246](index=246&type=chunk) - The company is cooperating with the government's request but cannot predict the outcome or estimate any potential loss from this matter[99](index=99&type=chunk)[246](index=246&type=chunk) [Risk Factors](index=48&type=section&id=Item%201A.%20Risk%20Factors) Key risks include a history of net losses and an accumulated deficit of **$221.5 million**, heavy revenue dependence on DecisionDx-Melanoma and TissueCypher after losing Medicare coverage for DecisionDx-SCC, and ongoing regulatory uncertainty for Laboratory Developed Tests (LDTs) - The company has a history of net losses and an accumulated deficit of **$221.5 million** as of June 30, 2025, raising concerns about sustained profitability[249](index=249&type=chunk) - Revenue is heavily dependent on DecisionDx-Melanoma and TissueCypher tests, as DecisionDx-SCC revenue is expected to decline significantly following the loss of Medicare coverage effective **April 24, 2025**[251](index=251&type=chunk) - The regulatory landscape for Laboratory Developed Tests (LDTs) remains a risk, despite a federal court vacating the FDA's final rule to regulate LDTs as medical devices, as future changes could still impose extensive FDA requirements[260](index=260&type=chunk)[266](index=266&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=55&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) There has been no material change in the planned use of net proceeds from the company's July 2019 IPO, with proceeds remaining invested in cash, cash equivalents, or highly liquid investment securities as of June 30, 2025 - As of June 30, 2025, the company has not used any net proceeds from its 2019 IPO, keeping them invested in cash equivalents or liquid securities[290](index=290&type=chunk) [Other Information](index=55&type=section&id=Item%205.%20Other%20Information) On May 8, 2025, CEO Derek Maetzold adopted a Rule 10b5-1 trading plan for the sale of up to **48,204 common shares** and **48,919 RSU-settled shares**, active from August 2025 to February 2026 - On May 8, 2025, CEO Derek Maetzold adopted a Rule 10b5-1 trading arrangement for the sale of company stock, scheduled from approximately **August 14, 2025, to February 13, 2026**[293](index=293&type=chunk)

[Financial & Operational Highlights](index=1&type=section&id=Financial%20%26%20Operational%20Highlights) Q2 2025 revenue was $86.2 million, a slight decrease, with core test volume growth and raised full-year guidance [Second Quarter Ended June 30, 2025](index=1&type=section&id=Second%20Quarter%20Ended%20June%2030%2C%202025) Q2 2025 revenues were $86.2 million, a slight decrease, impacted by coverage decisions, with total test reports up 6% Q2 2025 Key Financial Metrics (in millions) | Metric | Q2 2025 | Q2 2024 | Change | | :--- | :--- | :--- | :--- | | Revenues | $86.2M | $87.0M | -0.9% | | Adjusted Revenues | $86.2M | $86.6M | -0.5% | | Gross Margin | 77% | 81% | -4 pp | | Adjusted Gross Margin | 80% | 83% | -3 pp | | Net Income | $4.5M | $8.9M | -49.2% | | Diluted EPS | $0.15 | $0.31 | -51.6% | | Adjusted EBITDA | $10.4M | $21.5M | -51.8% | Q2 2025 Test Report Volume | Test | Q2 2025 Reports | Q2 2024 Reports | Change | | :--- | :--- | :--- | :--- | | Total Test Reports | 26,574 | 25,102 | +6% | | DecisionDx-Melanoma | 9,981 | 9,585 | +4% | | TissueCypher | 9,170 | 4,782 | +92% | | DecisionDx-SCC | 4,762 | 4,277 | +11% | | IDgenetix | 1,027 | 4,903 | -79% | - Revenue and test volume were **negatively impacted** by the Novitas LCD deeming DecisionDx-SCC noncovered and the discontinuation of the IDgenetix test[4](index=4&type=chunk) [Six Months Ended June 30, 2025](index=2&type=section&id=Six%20Months%20Ended%20June%2030%2C%202025) H1 2025 revenues increased 9% to $174.2 million, with total test reports up 11%, but a net loss of $21.3 million due to amortization H1 2025 Key Financial Metrics (in millions) | Metric | H1 2025 | H1 2024 | Change | | :--- | :--- | :--- | :--- | | Revenues | $174.2M | $160.0M | +9% | | Adjusted Revenues | $176.2M | $159.0M | +11% | | Net (Loss) Income | ($21.3M) | $6.4M | N/A | | Diluted (Loss) EPS | ($0.74) | $0.22 | N/A | | Adjusted EBITDA | $23.4M | $32.1M | -27% | H1 2025 Test Report Volume | Test | H1 2025 Reports | H1 2024 Reports | Change | | :--- | :--- | :--- | :--- | | Total Test Reports | 50,976 | 45,990 | +11% | | DecisionDx-Melanoma | 18,602 | 17,969 | +4% | | TissueCypher | 16,602 | 8,211 | +102% | | DecisionDx-SCC | 9,137 | 7,854 | +16% | | IDgenetix | 3,605 | 8,981 | -60% | [Cash Position and 2025 Outlook](index=3&type=section&id=Cash%20Position%20and%202025%20Outlook) The company held **$275.9 million** in cash and raised full-year 2025 revenue guidance to **$310-320 million** - The company held **$275.9 million** in cash, cash equivalents, and marketable investment securities as of June 30, 2025[8](index=8&type=chunk) - Full-year 2025 revenue guidance was raised to **$310-320 million** from the prior range of $287-297 million[1](index=1&type=chunk)[9](index=9&type=chunk) [Business Accomplishments and Highlights](index=3&type=section&id=Second%20Quarter%20and%20Recent%20Accomplishments%20and%20Highlights) The company achieved significant milestones, including FDA Breakthrough Device designation for DecisionDx-Melanoma and the acquisition of Previse [Dermatology](index=3&type=section&id=Dermatology) DecisionDx-Melanoma received FDA Breakthrough Device designation, and DecisionDx-SCC saw new studies and a reconsideration request - DecisionDx-Melanoma was granted **Breakthrough Device designation** by the U.S. FDA[12](index=12&type=chunk) - A real-world study showed DecisionDx-Melanoma was associated with a **32% reduction in mortality risk** compared to untested patients[12](index=12&type=chunk) - A reconsideration request was submitted for the Novitas LCD regarding DecisionDx-SCC, with two new studies supporting its clinical utility[12](index=12&type=chunk)[13](index=13&type=chunk) [Gastroenterology](index=4&type=section&id=Gastroenterology) The acquisition of Previse was completed, expected to expand GI offerings for Barrett's esophagus and other GI diseases - The acquisition of Previse (Capsulomics, Inc.) was completed, expected to **expand Castle's GI offerings** for Barrett's esophagus[14](index=14&type=chunk) [Uveal Melanoma](index=4&type=section&id=Uveal%20Melanoma) New data supports adding PRAME gene expression to DecisionDx-UM to refine metastatic risk prediction for uveal melanoma - New data from an independent validation study supports adding PRAME gene expression to DecisionDx-UM to **refine metastatic risk prediction**[15](index=15&type=chunk) [Pipeline Initiatives](index=4&type=section&id=Pipeline%20Initiatives) A collaboration with SciBase was initiated to develop a diagnostic test for predicting flares in atopic dermatitis patients - A collaboration and license agreement was signed with SciBase to develop a diagnostic test for predicting flares in atopic dermatitis[16](index=16&type=chunk) [Corporate](index=4&type=section&id=Corporate) CEO Derek Maetzold received a Lifetime Achievement Award, and the company earned multiple Top Workplaces awards - CEO Derek Maetzold received a **Lifetime Achievement Award** and was named a 2025 Most Admired CEO[18](index=18&type=chunk)[19](index=19&type=chunk) - The company earned several 2025 Top Workplaces awards for its healthcare industry ranking and culture excellence[18](index=18&type=chunk) [Financial Statements (Unaudited)](index=8&type=section&id=Financial%20Statements%20(Unaudited)) Unaudited financial statements show a H1 2025 net loss of $21.3 million, total assets of $544.7 million, and positive operating cash flow [Condensed Consolidated Statements of Operations](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) H1 2025 net revenues grew to $174.2 million, but a $30.3 million amortization expense led to a $21.3 million net loss Condensed Consolidated Statements of Operations (in thousands) | | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | **Net Revenues** | **$174,176** | **$159,976** | | Total operating expenses, net | $206,355 | $160,435 | | *Amortization of acquired intangible assets* | *$30,286* | *$4,494* | | Operating (loss) income | ($32,179) | ($459) | | **Net (loss) income** | **($21,325)** | **$6,386** | | **Diluted (loss) earnings per share** | **($0.74)** | **$0.22** | [Condensed Consolidated Balance Sheets](index=10&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets reached $544.7 million, with liabilities at $89.4 million and equity stable at $455.4 million Condensed Consolidated Balance Sheet Highlights (in thousands) | | June 30, 2025 | Dec 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $82,233 | $119,709 | | Marketable investment securities | $193,697 | $173,421 | | **Total Assets** | **$544,729** | **$531,235** | | **Total Liabilities** | **$89,353** | **$75,400** | | **Total Stockholders' Equity** | **$455,376** | **$455,835** | [Condensed Consolidated Statements of Cash Flows](index=11&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) H1 2025 operating cash flow was $14.8 million, but investing activities led to a $37.5 million decrease in cash Condensed Consolidated Statement of Cash Flows Highlights (in thousands) | | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $14,785 | $17,163 | | Net cash used in investing activities | ($50,809) | ($41,118) | | Net cash (used in) provided by financing activities | ($1,452) | $10,686 | | **Net Change in Cash and Cash Equivalents** | **($37,476)** | **($13,269)** | [Non-GAAP Financial Measures](index=5&type=section&id=Non-GAAP%20Financial%20Measures) Non-GAAP metrics show Q2 2025 Adjusted Revenues of $86.2 million and Adjusted EBITDA of $10.4 million [Reconciliation of Adjusted Revenues, Gross Margin, and Net Income Per Share](index=12&type=section&id=Reconciliation%20of%20Adjusted%20Revenues%2C%20Gross%20Margin%2C%20and%20Net%20Income%20Per%20Share) H1 2025 Adjusted Revenues were $176.2 million, with a $20.1 million amortization adjustment leading to a $1.2 million Adjusted Net Loss Reconciliation of Key Non-GAAP Metrics (Q2 2025 vs Q2 2024) (in thousands) | | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Net revenues (GAAP) | $86,188 | $87,002 | | **Adjusted Revenues (Non-GAAP)** | **$86,182** | **$86,639** | | Gross Margin percentage (GAAP) | 77.3% | 80.7% | | **Adjusted Gross Margin percentage (Non-GAAP)** | **79.5%** | **83.2%** | - For H1 2025, a **$20.1 million one-time adjustment** for accelerated amortization of IDgenetix significantly impacted GAAP net loss[44](index=44&type=chunk)[45](index=45&type=chunk) [Reconciliation of Adjusted EBITDA](index=13&type=section&id=Reconciliation%20of%20Adjusted%20EBITDA) Q2 2025 Adjusted EBITDA was $10.4 million, a decrease from Q2 2024, with H1 2025 Adjusted EBITDA at $23.4 million Reconciliation of Adjusted EBITDA (in thousands) | | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Net income (loss) | $4,523 | $8,920 | ($21,325) | $6,386 | | Adjustments | $5,848 | $12,619 | $44,711 | $25,697 | | **Adjusted EBITDA (Non-GAAP)** | **$10,371** | **$21,539** | **$23,386** | **$32,083** | [Supplementary Information](index=5&type=section&id=Supplementary%20Information) This section provides conference call details, company overview, and forward-looking statements with associated risk factors [Conference Call and Webcast Details](index=5&type=section&id=Conference%20Call%20and%20Webcast%20Details) A conference call and webcast are scheduled for August 4, 2025, at 4:30 p.m. ET to discuss Q2 2025 results - A conference call is scheduled for **August 4, 2025, at 4:30 p.m. ET** to discuss Q2 2025 results[20](index=20&type=chunk) [About Castle Biosciences](index=6&type=section&id=About%20Castle%20Biosciences) Castle Biosciences is a diagnostics company focused on innovative tests for skin cancers, Barrett's esophagus, and uveal melanoma - The company's portfolio includes tests for skin cancers, Barrett's esophagus, and uveal melanoma, with ongoing R&D[29](index=29&type=chunk) [Forward-Looking Statements](index=6&type=section&id=Forward-Looking%20Statements) This section contains forward-looking statements, including revenue guidance, with a caution that actual results may differ due to risks - The press release includes forward-looking statements concerning 2025 revenue guidance and product developments[31](index=31&type=chunk) - Investors are cautioned that actual results may differ materially due to various risks detailed in SEC filings[32](index=32&type=chunk)

Core Insights - Castle Biosciences reported Q2 2025 revenue of $86 million, a slight decrease from $87 million in Q2 2024, while total test reports for core revenue drivers increased by 33% year-over-year [1][4] - The company raised its full-year 2025 revenue guidance to a range of $310-320 million from the previous range of $287-297 million, reflecting strong performance in its core tests [7] Financial Highlights - Q2 2025 revenues were $86.2 million, compared to $87.0 million in Q2 2024, with adjusted revenues of $86.2 million, slightly down from $86.6 million in the same period last year [4] - Total test reports delivered in Q2 2025 were 26,574, a 6% increase from 25,102 in Q2 2024 [4] - Gross margin for Q2 2025 was 77%, with an adjusted gross margin of 80%, compared to 81% and 83% in Q2 2024, respectively [4] - Net cash provided by operations was $20.8 million, down from $24.0 million in Q2 2024 [4] Operational Highlights - The company delivered 9,981 DecisionDx-Melanoma test reports in Q2 2025, up from 9,585 in Q2 2024, and 9,170 TissueCypher Barrett's Esophagus test reports, significantly up from 4,782 in the same period last year [4] - The DecisionDx-SCC test reports delivered were 4,762, compared to 4,277 in Q2 2024, despite the impact of the Novitas local coverage determination [4] - The company discontinued its IDgenetix test offering in May 2025, which affected test report volumes [4] Strategic Developments - Castle Biosciences completed the acquisition of Previse and announced a collaboration with SciBase, aimed at enhancing its gastrointestinal offerings and developing new diagnostic tests [3][10] - The company is focused on executing its current test portfolio while investing in future growth initiatives [3] Market Position and Future Outlook - The company anticipates continued growth in test volumes and revenue, supported by the clinical value of its tests [2] - The DecisionDx-Melanoma test has received Breakthrough Device designation from the FDA, which may enhance its market position [13] - The company aims to create a multiomics approach for improved patient care in Barrett's esophagus through its acquisition of Previse [10]

Company Overview - Castle Biosciences, Inc. is a diagnostics company focused on improving health through innovative tests that guide patient care [3] - The company aims to transform disease management by prioritizing patients, clinicians, employees, and investors [3] Upcoming Presentation - The executive management of Castle Biosciences is scheduled to present a company overview at the Canaccord Genuity 45 Annual Growth Conference on August 12, 2025, at 12:30 p.m. Eastern time [1] - A live audio webcast of the presentation will be available on the company's website, with a replay accessible after the live broadcast [2] Product Portfolio - Castle's current portfolio includes tests for skin cancers, Barrett's esophagus, and uveal melanoma [4] - The company is actively developing tests for diseases with high clinical need, including a test for guiding systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment [4]

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Castle Biosciences, Inc. due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected on August 4, with a consensus estimate of a quarterly loss of $0.51 per share, reflecting a year-over-year change of -264.5% [3]. - Revenues are projected to be $73.89 million, down 15.1% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 26% lower in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate matches the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictor for positive readings [9][10]. - Castle Biosciences currently holds a Zacks Rank of 4, making it challenging to predict an earnings beat [12][13]. Historical Performance - In the last reported quarter, Castle Biosciences was expected to post a loss of $0.08 per share but actually reported a loss of -$0.20, resulting in a surprise of -150.00% [14]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [15]. Industry Comparison - Moderna, another player in the Zacks Medical - Biomedical and Genetics industry, is expected to report a loss of $2.99 per share, with revenues projected at $127.17 million, down 47.2% year-over-year [19][20]. - Moderna's consensus EPS estimate has been revised 1.4% lower, but it has a positive Earnings ESP of +7.22% and a Zacks Rank of 3, indicating a likelihood of beating the consensus estimate [20][21].

Core Insights - Castle Biosciences' CEO Derek Maetzold has been recognized as a 2025 Most Admired CEO by the Houston Business Journal for his exceptional leadership and contributions to the community [3][4] - The award highlights the importance of financial stewardship and fostering inclusive workplace cultures, which are key aspects of Maetzold's leadership approach [3][4] Company Overview - Castle Biosciences (Nasdaq: CSTL) is a diagnostics company focused on improving health through innovative tests that guide patient care [5] - The company aims to transform disease management by prioritizing the needs of patients, clinicians, employees, and investors [5] Product Portfolio - Castle's current portfolio includes diagnostic tests for skin cancers, Barrett's esophagus, and uveal melanoma [6] - The company is also engaged in research and development for additional tests addressing high clinical needs, including a test for guiding systemic therapy selection for patients with moderate-to-severe atopic dermatitis [6]

Core Insights - Castle Biosciences, Inc. announced that its DecisionDx-Melanoma test received Breakthrough Device designation from the FDA, aimed at improving patient care for those diagnosed with stage I-III cutaneous melanoma [1][3] Company Overview - Castle Biosciences is a diagnostics company focused on innovative tests that guide patient care, with a mission to transform disease management by prioritizing patients, clinicians, employees, and investors [5] - The company has a portfolio that includes tests for skin cancers, Barrett's esophagus, and uveal melanoma, and is engaged in R&D for additional tests in high clinical need areas [6] Product Details - DecisionDx-Melanoma is a gene expression profile test that assesses a patient's risk of sentinel lymph node positivity and melanoma recurrence/metastasis, integrating tumor biology with clinical factors [4] - The test has been validated through over 10,000 patient samples and is supported by more than 50 peer-reviewed studies, demonstrating its clinical value and association with improved patient survival [4] - As of March 31, 2025, DecisionDx-Melanoma has been ordered over 200,000 times for patients diagnosed with cutaneous melanoma [4]

Core Insights - Castle Biosciences, Inc. has received multiple awards in the 2025 Top Workplaces program, including a third consecutive national Healthcare Industry Top Workplaces award, ranking third in its size category, and a fourth consecutive regional Arizona Top Workplaces award [1][2] - The company has also been recognized for its Culture Excellence in various categories such as Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership, and Purpose & Values [1][2] Company Overview - Castle Biosciences is a leading diagnostics company focused on improving health through innovative tests that guide patient care, with a mission to transform disease management by prioritizing patients, clinicians, employees, and investors [3] - The company's current portfolio includes tests for skin cancers, Barrett's esophagus, and uveal melanoma, along with ongoing research and development for additional tests addressing high clinical needs [4] Awards and Recognition - The Top Workplaces awards are based on anonymous employee feedback collected through a third-party survey, which evaluates workplace experience and culture themes indicative of successful organizations [2] - Castle's awards in specific categories highlight its commitment to fostering a people-first culture, which is seen as a catalyst for innovation and impact [2][5]